TERIFLUNOMIDE ( DrugBank: Teriflunomide )

3 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
13	多発性硬化症／視神経脊髄炎	262
25	進行性多巣性白質脳症	1
26	HTLV-1関連脊髄症	1

13. 多発性硬化症／視神経脊髄炎

臨床試験数 : 3,342 / 薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241

diseases per page:

Showing 1 to 10 of 262 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2020-005899-36-SK (EUCTR)	21/02/2022	22/11/2021	Efficacy and safety of remibrutinib compared to teriflunomidein participants with relapsing multiple ...	A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of ...	Multiple Sclerosis MedDRA version: 21.0;Level: PT;Classification code 10080700;Term: Relapsing multi ...	Product Name: remibrutinib Product Code: LOU064 INN or Proposed INN: Remibrutinib Trade Name: Aubagio Pr ...	Novartis Pharma AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	800	Phase 3	United States;Serbia;Hong Kong;Slovakia;Spain;Chile;Russian Federation;Colombia;Italy;Switzerland;In ...
2	EUCTR2020-005899-36-ES (EUCTR)	11/02/2022	29/12/2021	Efficacy and safety of remibrutinib compared to teriflunomidein participants with relapsing multiple ...	A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of ...	Multiple Sclerosis MedDRA version: 21.0;Level: PT;Classification code 10080700;Term: Relapsing multi ...	Product Name: remibrutinib Product Code: LOU064 INN or Proposed INN: Remibrutinib Trade Name: Aubagio Pr ...	Novartis Farmacéutica S.A.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	800	Phase 3	Slovakia;Spain
3	EUCTR2020-005929-89-ES (EUCTR)	11/02/2022	22/12/2021	Efficacy and safety of remibrutinib compared to teriflunomidein participants with relapsing multiple ...	A randomized, double-blind, double-dummy, parallel-group study,comparing the efficacy and safety of ...	Multiple Sclerosis MedDRA version: 21.0;Level: PT;Classification code 10080700;Term: Relapsing multi ...	Product Name: remibrutinib Product Code: LOU064 INN or Proposed INN: Remibrutinib Trade Name: Aubagio Pr ...	Novartis Farmacéutica S.A.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	800	Phase 3	United States;Portugal;Estonia;Slovakia;Greece;Spain;Russian Federation;Italy;India;France;South Afr ...
4	EUCTR2020-005929-89-SE (EUCTR)	01/02/2022	09/11/2021	Efficacy and safety of remibrutinib compared to teriflunomidein participants with relapsing multiple ...	A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of ...	Multiple Sclerosis MedDRA version: 21.0;Level: PT;Classification code 10080700;Term: Relapsing multi ...	Product Name: remibrutinib Product Code: LOU064 INN or Proposed INN: Remibrutinib Trade Name: Aubagio Pr ...	Novartis Pharma AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	800	Phase 3	United States;Portugal;Estonia;Slovakia;Greece;Spain;Russian Federation;Italy;India;France;South Afr ...
5	NCT05147220 (ClinicalTrials.gov)	December 16, 2021	24/11/2021	Efficacy and Safety of Remibrutinib Compared to Teriflunomidein Participants With Relapsing Multiple ...	A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of ...	Relapsing Multiple Sclerosis	Drug: Remibrutinib;Drug: Teriflunomide	Novartis Pharmaceuticals	NULL	Recruiting	18 Years	55 Years	All	800	Phase 3	United States
6	NCT05156281 (ClinicalTrials.gov)	December 13, 2021	1/12/2021	Efficacy and Safety of Remibrutinib Compared to Teriflunomidein Participants With Relapsing Multiple ...	A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of ...	Relapsing Multiple Sclerosis	Drug: Remibrutinib;Drug: Teriflunomide	Novartis Pharmaceuticals	NULL	Recruiting	18 Years	55 Years	All	800	Phase 3	United States
7	EUCTR2019-004857-10-HU (EUCTR)	06/05/2021	18/03/2021	To Evaluate the Efficacy and Safety of Fenebrutinib Compared with Teriflunomidein Adult Patients wit ...	A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE TH ...	Relapsing multiple sclerosis (RMS) MedDRA version: 20.0;Level: PT;Classification code 10048393;Term: ...	Product Name: fenebrutinib Product Code: RO7010939 INN or Proposed INN: FENEBRUTINIB Trade Name: Aubagi ...	F. Hoffmann-La Roche Ltd	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	734	Phase 3	Portugal;France;United States;Hungary;Finland;Germany;Netherlands
8	EUCTR2020-000644-55-DE (EUCTR)	22/04/2021	17/06/2020	Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's TyrosineKinase (BTK) Inhibitor Tolebru ...	A Phase 3, randomized, double-blind efficacy and safety study comparing SAR442168 to teriflunomide(A ...	Relapsing Multiple Sclerosis MedDRA version: 21.0;Level: PT;Classification code 10080700;Term: Relap ...	Product Code: SAR442168 INN or Proposed INN: Not available Other descriptive name: PRN2246 Trade Name: ...	Genzyme Corporation	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	1200	Phase 3	United States;Portugal;Serbia;Slovakia;Greece;Spain;Ukraine;Israel;Chile;Russian Federation;Switzerl ...
9	EUCTR2019-004857-10-DE (EUCTR)	29/03/2021	11/12/2020	To Evaluate the Efficacy and Safety of Fenebrutinib Compared with Teriflunomidein Adult Patients wit ...	A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE TH ...	Relapsing multiple sclerosis (RMS) MedDRA version: 20.0;Level: PT;Classification code 10048393;Term: ...	Product Name: fenebrutinib Product Code: RO7010939 INN or Proposed INN: FENEBRUTINIB Trade Name: Aubagi ...	F. Hoffmann-La Roche Ltd	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	736	Phase 3	Portugal;France;United States;Hungary;Finland;Netherlands;Germany;Italy
10	NCT04586023 (ClinicalTrials.gov)	March 24, 2021	8/10/2020	Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With TeriflunomideIn Relapsing Mu ...	A Phase III Multicenter Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The ...	Relapsing Multiple Sclerosis	Drug: fenebrutinib;Drug: teriflunomide;Drug: placebo	Hoffmann-La Roche	NULL	Recruiting	18 Years	55 Years	All	736	Phase 3	United States;Austria;Brazil;Bulgaria;Canada;Denmark;France;Greece;Guatemala;India;Italy;Korea, Repu ...

First Previous1 2 3 4 5…27Next Last

先頭へ

25. 進行性多巣性白質脳症

臨床試験数 : 25 / 薬物数 : 35 - (DrugBank : 21) / 標的遺伝子数 : 8 - 標的パスウェイ数 : 37

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01970410 (ClinicalTrials.gov)	October 2013	22/10/2013	Sub-Study: Analysis of JCV Antibody Index in MS Patients Treated With Teriflunomide - SWITCH-JCV	Switching Relapsing Multiple Sclerosis Patients Treated With Natalizumab at Risk for Progressive Mul ...	Multiple Sclerosis	Drug: teriflunomide	Providence Health & Services	Multiple Sclerosis Center of Northeastern New York	Active, not recruiting	21 Years	60 Years	All	41	Phase 4	United States

First Previous1Next Last

26. HTLV-1関連脊髄症

臨床試験数 : 28 / 薬物数 : 48 - (DrugBank : 28) / 標的遺伝子数 : 38 - 標的パスウェイ数 : 127

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04799288 (ClinicalTrials.gov)	September 24, 2021	13/3/2021	Teriflunomide in HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis	Phase I/II Study of Teriflunomide in HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis	HAM/TSP	Drug: Teriflunomide	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Recruiting	18 Years	N/A	All	16	Phase 1/Phase 2	United States

First Previous1Next Last

先頭へ